Mutational analysis of the "turn" of helix clamp motif of HIV-1 reverse transcriptase

Biochemical and Biophysical Research Communications

Volumn 377, Issue 3, 2008, Pages 915-920

  Wang, Yong Xiang ^a   Zhang, Hao Jie ^b   Xu, Jing ^a   Zheng, Bo Jian ^b   Wen, Yu Mei ^a  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

HIV 1; Polymerase activity; Processivity; Replication; Reverse transcriptase; Turn of helix clamp motif

Indexed keywords

HELIX LOOP HELIX PROTEIN; MUTANT PROTEIN; RNA DIRECTED DNA POLYMERASE;

ALPHA HELIX; ARTICLE; DNA BINDING; ENZYME ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; VIRUS REPLICATION;

AMINO ACID MOTIFS; AMINO ACID SUBSTITUTION; CELL LINE; DNA; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MUTATION; PROTEIN STRUCTURE, SECONDARY; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 56049097627     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.10.106     Document Type: Article

References (23)

1. Goff S.P. Retroviral reverse transcriptase: synthesis, structure, and function. J. Acquir. Immune Defic. Syndr. 3 (1990) 817-831
2. Smith A.J., Srinivasakumar N., Hammarskjold M.L., and Rekosh D. Requirements for incorporation of Pr160gag-pol from human immunodeficiency virus type 1 into virus-like particles. J. Virol. 67 (1993) 2266-2275
3. Mak J., and Kleiman L. Primer tRNAs for reverse transcription. J. Virol. 71 (1997) 8087-8095
4. Mak J., Jiang M., Wainberg M.A., Hammarskjold M.L., Rekosh D., and Kleiman L. Role of Pr160gag-pol in mediating the selective incorporation of tRNA(Lys) into human immunodeficiency virus type 1 particles. J. Virol. 68 (1994) 2065-2072
5. Khorchid A., Javanbakht H., Wise S., Halwani R., Parniak M.A., Wainberg M.A., and Kleiman L. Sequences within Pr160gag-pol affecting the selective packaging of primer tRNA(Lys3) into HIV-1. J. Mol. Biol. 299 (2000) 17-26
6. Lightfoote M.M., Coligan J.E., Folks T.M., Fauci A.S., Martin M.A., and Venkatesan S. Structural characterization of reverse transcriptase and endonuclease polypeptides of the acquired immunodeficiency syndrome retrovirus. J. Virol. 60 (1986) 771-775
7. Rodgers D.W., Gamblin S.J., Harris B.A., Ray S., Culp J.S., Hellmig B., Woolf D.J., Debouck C., and Harrison S.C. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 92 (1995) 1222-1226
8. Poch O., Sauvaget I., Delarue M., and Tordo N. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J. 8 (1989) 3867-3874
9. Hermann T., Meier T., Gotte M., and Heumann H. The 'helix clamp' in HIV-1 reverse transcriptase: a new nucleic acid binding motif common in nucleic acid polymerases. Nucleic Acids Res. 22 (1994) 4625-4633
10. Beard W.A., Minnick D.T., Wade C.L., Prasad R., Won R.L., Kumar A., Kunkel T.A., and Wilson S.H. Role of the "helix clamp" in HIV-1 reverse transcriptase catalytic cycling as revealed by alanine-scanning mutagenesis. J. Biol. Chem. 271 (1996) 12213-12220
11. Beard W.A., Stahl S.J., Kim H.R., Bebenek K., Kumar A., Strub M.P., Becerra S.P., Kunkel T.A., and Wilson S.H. Structure/function studies of human immunodeficiency virus type 1 reverse transcriptase. Alanine scanning mutagenesis of an alpha-helix in the thumb subdomain. J. Biol. Chem. 269 (1994) 28091-28097
12. Bebenek K., Beard W.A., Casas-Finet J.R., Kim H.R., Darden T.A., Wilson S.H., and Kunkel T.A. Reduced frameshift fidelity and processivity of HIV-1 reverse transcriptase mutants containing alanine substitutions in helix H of the thumb subdomain. J. Biol. Chem. 270 (1995) 19516-19523
13. Zhang H., Zhou Y., Alcock C., Kiefer T., Monie D., Siliciano J., Li Q., Pham P., Cofrancesco J., Persaud D., and Siliciano R.F. Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J. Virol. 78 (2004) 1718-1729
14. Chang L.J., Urlacher V., Iwakuma T., Cui Y., and Zucali J. Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system. Gene Ther. 6 (1999) 715-728
15. Weiss A., Wiskocil R.L., and Stobo J.D. The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level. J. Immunol. 133 (1984) 123-128
16. Le Grice S.F., Naas T., Wohlgensinger B., and Schatz O. Subunit-selective mutagenesis indicates minimal polymerase activity in heterodimer-associated p51 HIV-1 reverse transcriptase. EMBO J. 10 (1991) 3905-3911
17. Jacques P.S., Wohrl B.M., Ottmann M., Darlix J.L., and Le Grice S.F. Mutating the "primer grip" of p66 HIV-1 reverse transcriptase implicates tryptophan-229 in template-primer utilization. J. Biol. Chem. 269 (1994) 26472-26478
18. Bakhanashvili M., and Hizi A. Interaction of the reverse transcriptase of human immunodeficiency virus type 1 with DNA. Biochemistry 33 (1994) 12222-12228
19. Avidan O., and Hizi A. The processivity of DNA synthesis exhibited by drug-resistant variants of human immunodeficiency virus type-1 reverse transcriptase. Nucleic Acids Res. 26 (1998) 1713-1717
20. Wang Y.X., Xu X., Luo C., Ma Z.M., Jiang H.L., Ding J.P., and Wen Y.M. A putative new domain target for anti-hepatitis B virus: residues flanking hepatitis B virus reverse transcriptase residue 306 (rtP306). J. Med. Virol. 79 (2007) 676-682
21. Wang Y.X., Xu X., Luo C., Ma Z.M., Jiang H.L., Ding J.P., and Wen Y.M. Mutational analysis revealed that conservation of hepatitis B virus reverse transcriptase residue 306 (rtP306) is crucial for encapsidation of pregenomic RNA. FEBS Lett. 581 (2007) 558-564
22. Hu J., and Seeger C. Expression and characterization of hepadnavirus reverse transcriptases. Methods Enzymol. 275 (1996) 195-208
23. Das K., Xiong X., Yang H., Westland C.E., Gibbs C.S., Sarafianos S.G., and Arnold E. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J. Virol. 75 (2001) 4771-4779